EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
NCT06923761
Recruiting
This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: GenesisCare Research, Adelaide, Not set +28 locations
Conditions: Advanced Solid Malignancy
Register for Updates
Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia
NCT05696522
Recruiting
Ventricular tachycardia (VT) is an abnormal rhythm arising from the bottom chambers (ventricles) of the heart. The hearts of most patients who develop VT have been previously damaged by a myocardial infarction (heart attack) or other heart muscle diseases (cardiomyopathies). The damage produces scar or fatty deposits that conduct electrical impulses slowly allowing VT to occur. Recurrent episodes of VT can compromise heart function and increase mortality. VT is prevented by special drugs but th... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/18/2025
Locations: St Bartholomew's Hospital, London, Not set
Conditions: Radiotherapy; Complications, Ventricular Tachycardia, Structural Heart Abnormality, Heart Failure
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Dothan, Alabama +795 locations
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer
NCT06547840
Recruiting
EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancer The dose escalation part of the study will primarily assess the safety and tolerability of MOv18 IgE in ascending dose cohorts, until the determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD). Part... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Bristol Haematology and Oncology Centre, Bristol, Not set +6 locations
Conditions: Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer
Register for Updates
Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography
NCT06386185
Recruiting
The goal of this observational study is to assess the efficacy that the addition of novel markers cardiac function, particularly of right ventricular (RV) function in echocardiography, and ECG have in detecting pulmonary hypertension. The main questions it aims to answer are: Can novel markers in ECG and echocardiography suggest the presence of PH? Can existing screening guidelines be improved with the addition of these markers?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Royal United Hospital NHS Foundation Trust, Bath, Banes +4 locations
Conditions: Pulmonary Hypertension
Register for Updates
pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure
NCT07029906
Recruiting
Beta-blocker tablets are an effective treatment for heart failure that make people live longer and reduce the need to be admitted to hospital. Many patients who are at high risk of death are prescribed beta-blockers, but later choose to stop taking them because of symptoms that they perceive to be side-effects. Some patients' symptoms may genuinely be side-effects due to the beta-blocker tablets, but, in reality, many of the symptoms which may lead to people stopping beta-blockers are actually e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Imperial College London, London, Not set
Conditions: Side-Effect, Heart Failure
Register for Updates
TherApeutics in Early ProState Cancer (TAPS02)
NCT05191680
Recruiting
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Addenbrooke's Hospital, Cambridge, Cambridgeshire +5 locations
Conditions: Prostate Cancer
Register for Updates
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637
Recruiting
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +254 locations
Conditions: Breast Cancer
Register for Updates
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356
Recruiting
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology), Los Angeles, California +14 locations
Conditions: Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Register for Updates
A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection to Standard Measurements of Lactate in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery and/or Valve Replacement.
NCT06602336
Recruiting
The main goal of this study is to see if a wearable device can reliably track changes in lactate levels in the body. We\'ll compare the device\'s readings to standard blood tests to ensure accuracy. If successful, this device could reduce the need for frequent blood tests during surgery recovery, making patients more comfortable. It might also be useful in emergency rooms for quick diagnoses, especially for patients with chest pain. This study will take place at Barts Hospital w... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/17/2025
Locations: Barts Health, London, Not set
Conditions: Coronary Artery Bypass, Coronary Artery Bypass Graft, Coronary Artery Bypass Graft Surgery (CABG), Valve Replacement, Valve Surgery, Cardiovascular, CABG
Register for Updates
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT03761108
Recruiting
The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving REGN5458 * How REGN5458 works in the body * How much REGN5458 is present in the blood * How REGN5458 may work to treat cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +39 locations
Conditions: Multiple Myeloma
Register for Updates
A Trial of Staff Time With Proned Patients in the ICU Using the 'BathMat'
NCT06844617
Recruiting
Proning is a way of helping people who are very sick and have trouble breathing. It involves lying patients on their front to get more oxygen into their body. This process happens in a part of the hospital called the Intensive Care Unit, and can last up to 16 hours per day. When in this position, doctors need to turn the patients' head and move their arms every 2-4 hours. Doctors call this repositioning. It helps prevent sores as well as other injuries. To do this, the health care team slide th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: North Bristol Trust, Bristol, Not set
Conditions: Acute Respiratory Distress Syndrome (ARDS), Proning, Intensive Care Medicine
Register for Updates